Filing summary
Entity clarification: The supplied filing is Nanophase Technologies Corporation’s Form 10-Q, not a standalone Solesence, Inc. filing. It covers Nanophase and its wholly owned Solésence, LLC subsidiary on a consolidated basis. The quarter ended September 30, 2022; amounts below are in thousands of dollars unless otherwise noted.
Business context and results
Nanophase focuses on beauty and life-science markets, including Solésence finished skin-care products, personal-care ingredients, and medical-diagnostics materials. Management says its strategic emphasis is skin health and diagnostics, while legacy advanced-materials markets are not a primary growth focus.
- Third-quarter revenue: $9,678, up 22% from $7,924. Product revenue was $9,673; other revenue was $5.
- Nine-month revenue: $29,056, up 31% from $22,110. Product revenue was $28,515; other revenue was $541.
- Product mix, Q3: Solésence $5,932; personal-care ingredients $2,903; advanced materials $843. Solésence and personal-care ingredient growth was partly offset by weaker advanced-materials sales.
- Profitability, Q3: Gross profit was $2,493 versus $2,978; gross margin was approximately 25.8% versus 37.6%. Operating loss was $634 versus operating income of $1,401; net loss was $750 versus net income of $1,363. Loss per share was $0.02.
- Profitability, nine months: Gross profit was $7,397 versus $7,522; gross margin was approximately 25.5% versus 34.0%. Operating loss was $406 versus operating income of $2,858; net loss was $638 versus net income of $2,714. Loss per share was $0.01.
- Costs: Q3 cost of revenue rose to $7,185 from $4,946. Management attributed margin pressure to higher material costs, inflation, manufacturing inefficiencies, overtime and hiring constraints, and costs of supporting growth. Q3 SG&A rose to $2,279 from $942 and included $230 of bad-debt expense; R&D increased to $848 from $635.
Cash, liquidity, debt, and balance sheet
- Cash was $510 at September 30, 2022, down from $657 at December 31, 2021. Current assets were $16,453 and current liabilities were $14,094, for working capital of $2,359.
- For the first nine months, operating cash flow was negative $2,397, versus positive $269 in 2021. Investing cash outflow was $1,798, mainly equipment and leasehold improvements; financing provided $4,048. Management cited growth-related increases in receivables and inventory as key uses of cash.
- The balance sheet reports a $5,358 related-party line of credit and $1,000 of related-party long-term debt. The borrowing note separately lists $3,358 outstanding on the A/R revolver and $3,000 on the inventory revolver; those amounts do not clearly reconcile to the balance-sheet line-of-credit figure in the supplied filing text.
- Related-party facilities mature March 31, 2024, bear rates described as prime plus 0.75% (with the term loan at 4.00%), and are secured by unencumbered company assets. Lenders are affiliates of a significant shareholder.
- Inventories increased to $9,596 from $6,095; accounts receivable rose to $5,368 from $3,937. Operating lease liabilities totaled $11,922, current and long-term combined.
Changes, outlook, risks, and unusual items
- Revenue growth reflected increased Solésence adoption and higher API sales to the largest personal-care customer. Medical-diagnostics revenue was limited in 2022; management notes demand for diagnostics materials had declined.
- Management expected gross-margin improvement to depend on production scaling, cost efficiency, product mix, and the ability to pass through input-cost increases. It characterized current margin pressure as potentially temporary, but cautioned that significant margin improvement might not occur through 2022 and the first half of 2023. No specific revenue or earnings guidance was provided.
- Management estimated capital spending for currently identified needs in 2022–2023 at $4 million to $14 million, depending on project execution, market conditions, and available funding. Funding was expected from operations, existing credit facilities, and potentially new debt.
- Five customers represented 77% of Q3 revenue and 70% of nine-month revenue. BASF, the largest customer, accounted for 30% of revenue in both periods. Customer concentration creates exposure to order changes and contract disputes.
- BASF sued over the zinc-oxide supply agreement, alleging breach of exclusivity and other provisions, and seeks unspecified damages and an injunction. Nanophase disputes the claims and filed a declaratory-judgment action. Management recorded no contingent loss; the filing says the loss range cannot be estimated. A court hearing on Nanophase’s motion to dismiss was expected in March 2023.
- A cyber-theft event in September and October resulted in a $188 loss recognized in Q3 and an additional $472 loss recognized after quarter-end.
- The filing reports a material weakness in inventory controls identified at year-end 2021. Remediation was ongoing and described as incomplete, although management reported progress. Management nevertheless concluded the financial statements were fairly stated.
- Management cited inflation, labor and supply-chain constraints, production capacity, uncertain demand, customer concentration, access to working capital, and the BASF dispute as risks. It said it did not knowingly source materials directly from Russia or Ukraine.
Important facts for investors to verify
- Confirm the issuer: this is Nanophase’s consolidated filing, including Solésence, not a standalone Solesence, Inc. 10-Q.
- Reconcile reported line-of-credit debt on the balance sheet with the separate A/R and inventory facility balances in the borrowing note.
- Monitor cash use, receivables and inventory levels, borrowing availability, and funding for the projected $4 million–$14 million capital program.
- Track gross-margin recovery, manufacturing capacity and efficiency, and the extent to which cost inflation can be passed to customers.
- Follow the BASF litigation and any potential effect on Solésence sales, supply arrangements, or access to production equipment and technology.
- Assess customer concentration, the cyber-theft losses, and completion of inventory-control remediation.